What ResolveMass Laboratories Inc. does

ResolveMass Laboratories Inc. is a privately held Canadian contract research and contract development & manufacturing organization (CRO/CDMO) headquartered at 500 Bd Cartier O, Laval, Quebec. The company provides specialized analytical, synthesis, and formulation services to pharmaceutical innovator companies, generic drug manufacturers, biotechnology firms, and medical device companies across North America and selected international markets (France, United Kingdom, Japan, Germany, Australia, South Korea, India). It distinguishes itself through three integrated capabilities: (1) GMP-compliant analytical and manufacturing services enabled by its Health Canada Drug Establishment Licence (3-002945-A), FDA Establishment Identifier 3042696771, and ISO 9001:2015 certification; (2) a comprehensive analytical instrumentation platform spanning mass spectrometry (LC-MS/MS, HRMS, MALDI-TOF), NMR, HPLC, GC-MS, GPC, DSC, and TGA; and (3) deep specialization in polymer synthesis for controlled drug delivery (PLGA, PLA, PCL and multiple block copolymers), generic peptide development (semaglutide, tirzepatide, liraglutide, lanreotide, nusinersen), and emerging modalities such as peptide-oligonucleotide conjugates.

The company's business model combines three revenue streams. Project-based professional services (CRO) generate the majority of revenue through custom organic and polymer synthesis, analytical method development, and bioanalytical work for drug discovery and development. Following Health Canada DEL acquisition, the company has expanded into managed CDMO services covering formulation development, analytical services, regulatory support, and GMP manufacturing for generic drug and peptide programs. A smaller catalog-product business sells biodegradable polymers, deuterated chemicals, and molecular building blocks. Pricing is quote-based and not publicly disclosed, reflecting the customized nature of project scopes. Go-to-market is sales-led: customer acquisition is driven by direct scientific consultation (booked via Calendly), technical blog content, webinars, and industry event participation including CPHI Americas 2026. Named customers include Eli Lilly, PharmaLube Technologies, MaxUnitech North America, General Dynamics Ordnance and Tactical Systems, Drexel University, McGill University, Pantheravax, Carterra, Usalco, Arca, and Plant Extracts Australia. Ownership and founder composition are not publicly disclosed beyond a general statement that the company was founded by experts with industry experience to revolutionize controlled drug delivery technologies.

Name

ResolveMass Laboratories Inc.

Legal name

ResolveMass Laboratories Inc.

Website

https://resolvemass.ca

Company type

Private

Operating status

Operating

Short description

ResolveMass Laboratories Inc. is a privately held Canadian CRO/CDMO headquartered in Laval, Quebec, providing GMP-compliant analytical testing, custom synthesis, polymer drug-delivery development, and generic peptide CDMO services to pharmaceutical, biotech, and medical device companies across North America, Europe, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Pharmaceutical CRO/CDMO Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical contract research
• Analytical testing services
• Custom polymer synthesis
• Mass spectrometry services
• GMP contract manufacturing

Headquarters

HQ city

Laval

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services (CRO): ResolveMass operates as a contract research organization providing specialized analytical testing and R&D services to pharmaceutical, biotech, and medical device companies. Services include custom synthesis, analytical method development, mass spectrometry, polymer characterization, and regulatory support. Revenue is generated through project-based contracts with clients across drug discovery, development, and manufacturing phases.
2. Contract Development and Manufacturing (CDMO): Following Health Canada Drug Establishment Licence acquisition, the company now executes full GMP projects including analytical testing, release support, and regulatory-ready documentation. This extends their service model from R&D to commercial manufacturing support.
3. Product Sales: Sale of specialty polymers including PLGA, PLA, PCL and related biodegradable polymers for controlled drug delivery applications. Products available through catalog and custom synthesis on request.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

ResolveMass Laboratories is a Canadian pharmaceutical CRO and CDMO providing custom organic and polymer synthesis, drug discovery support, generic peptide and oligonucleotide development, GMP-compliant manufacturing, and a comprehensive analytical services portfolio (mass spectrometry, NMR, HPLC, GC-MS, GPC, DSC, TGA, bioanalytical, E&L, nitrosamine, stability studies). It also sells specialty research materials including biodegradable polymers (PLGA, PLA, PCL and block copolymers), deuterated chemicals, and molecular building blocks.

Product overview

ResolveMass Laboratories Inc. is a Canadian pharmaceutical CRO and CDMO offering a comprehensive portfolio of contract research and manufacturing services alongside research chemical products. The portfolio consists of two main pillars: (1) Physical products including biodegradable polymer research materials (PLGA, PLA, PCL in various block copolymer configurations such as mPEG-b-PLGA, PLGA-PEG-PLGA, mPEG-PLA, PCL-PEG-PCL, PLA-PEG-PLA, PEG-PCL, PLA-PCL), deuterated chemicals, and molecular building blocks for pharmaceutical research; and (2) Extensive service offerings spanning drug discovery services (custom synthesis, isotopic labeling, medicinal chemistry, ADC services, CMC services), generic drug development CDMO services (formulation development, analytical services, regulatory support, GMP manufacturing), custom synthesis services (organic synthesis, polymer synthesis, cyclodextrin dendrimers, deuterated chemicals, POC synthesis), and analytical services (mass spectrometry including LC-MS/MS/HRMS/MALDI-TOF, NMR, HPLC, GPC, DSC, TGA, GC-FID/GC-MS, bioanalytical services, extractables & leachables testing, nitrosamine analysis, stability studies, and peptide characterization). The company operates as a single unified contract research organization serving pharmaceutical, biotech, and medical device clients across North America with GMP-compliant capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Biodegradable Polymers (PLGA, PLA, PCL and Block Copolymers)

Quantifiable outcome

• Integrated R&D to GMP capability enabling zero handoffs between development phases
• +1 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Patheon (Thermo Fisher Scientific): One of the largest global CDMOs (now part of Thermo Fisher's Pharma Services), offering end-to-end drug development and manufacturing across small molecules and biologics. Comparable as a broad incumbent serving the same CRO/CDMO buyer base as ResolveMass.
• Catalent: Global CDMO with extensive peptide, oral solid dose, and biologics capabilities, recently announced major peptide capacity expansions. Comparable as a scaled incumbent competing for the same peptide CDMO and analytical services contracts.
• Pharmaron: Global CRO/CDMO offering drug discovery, process R&D, and GMP manufacturing services with strong mass spectrometry and analytical capabilities. Comparable as a diversified CRO/CDMO with overlapping synthetic chemistry and analytical service lines.
• WuXi AppTec: China-headquartered global CRO/CDMO with end-to-end drug discovery, development, and manufacturing services. Comparable as a large-scale CRO/CDMO competing for the same small-molecule and analytical work.
• Eurofins Scientific: Global leader in bioanalytical, pharmaceutical, and contract laboratory services with extensive mass spectrometry footprint. Comparable as a broad testing laboratory and CRO incumbent serving pharmaceutical clients across similar service lines.
• Charles River Laboratories: Global CRO offering discovery, safety assessment, and manufacturing support services to pharma and biotech. Comparable as a diversified contract research incumbent with overlapping bioanalytical and CMC capabilities.

Direct peers

• Corden Pharma: European-headquartered CDMO with strong peptide and small-molecule API capabilities. Comparable as a specialized peptide and API CDMO competing directly for generic peptide CDMO programs.
• PolyPeptide Group: Specialty CDMO focused exclusively on peptide and oligonucleotide manufacturing for pharmaceutical and biotech clients. Comparable as a specialized peptide CDMO targeting the same GLP-1 generic and peptide-oligonucleotide opportunities as ResolveMass.
• Nucro-Technics: Canadian contract research organization in Scarborough, Ontario, providing preclinical, analytical, and bioanalytical services. Comparable as a Canadian CRO with overlapping mass spectrometry and pharmaceutical analytical capabilities.
• Dalton Pharma Services: Canadian CRO/CDMO based in Mississauga, Ontario, offering API development, analytical services, and GMP manufacturing. Directly comparable to ResolveMass as a mid-sized Canadian CDMO with integrated R&D-to-GMP capabilities serving pharma and biotech clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ResolveMass Laboratories Inc.